Feldan Therapeutics and Elasmogen announce research agreement with Amgen

Agreement to develop intracellular biologics

10-May-2017 - United Kingdom

Elasmogen Ltd, focused on the development of next generation biologics, and Feldan therapeutics, focused on intracellular delivery of proteins, today announce a research collaboration with Amgen, to develop and deliver novel intracellular biologics. The collaboration combines the unique capabilities of Feldan’s Shuttle platform and Elasmogen’s soloMER™ technology to develop the delivery system and binding domains to two undisclosed intracellular targets for Amgen.

The Feldan Shuttle technology is a novel peptide-based delivery method that enables the highly efficient introduction of foreign proteins into cells. Elasmogen’s soloMER’s are the smallest naturally occurring binding domains. Their small size and robust nature, particularly the resistance to changes in pH and ability to bind in intracellular conditions makes them the perfect complement to Feldan’s technology.

“Currently all approved biologic antibody therapeutics act on extracellular targets but intracellular delivery enables access to a much greater number of targets,” said François-Thomas Michaud, CEO, Feldan Therapeutics. “Intracellular delivery and binding of biologics can bridge the gap between small molecules and biologics.”

“This is an exciting opportunity to demonstrate the performance and capabilities of the combined Shuttle-soloMER technology. The expertise provided by Amgen will significantly accelerate the development of this potential new class of therapeutics,” said Caroline Barelle, CEO, Elasmogen.

In 2016, Feldan and Elasmogen established an exclusive partnership for the development of intracellular biologics. Working together, their research teams have demonstrated both intracellular and intranuclear delivery of soloMER binding domains.

https://www.bionity.com/en/news/163143/feldan-therapeutics-and-elasmogen-announce-research-agreement-with-amgen.html